Clinical trials: Drug Drug Interaction Study
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects
This first-in-human study has three parts. In Parts A and B, the safety, tolerability, and pharmacokinetics (PK) will be evaluated following administration of single and multiple doses of KRP-A218, including food-effect.
- Trial name
- NCT04908800
- Testing
- KRP-A218, itraconazole
- Where
- United Kingdom
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Kyorin Pharmaceutical Co.,Ltd
Healthy
Drug-Food Interaction Study of Seville Orange Juice and Colchicine
Seville orange juice is an inhibitor of the intestinal cytochrome P450 (CYP) 3A4 enzyme, one of the enzymes responsible for the metabolism of colchicine.
- Trial name
- NCT00960193
- Testing
- Colchicine, Seville Orange Juice
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy Volunteers
Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin
This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.
- Trial name
- NCT01057433
- Testing
- Pitavastatin (NK-104), Lopinavir/ritonavir
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Major Depressive Disorder
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
The purpose of this study is to measure if there is any difference in how the body breaks down or inactivates either fluoxetine or LY2216684 when both of these medicines are given together.
- Trial name
- NCT01243957
- Testing
- LY2216684, Fluoxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Fabry Disease
Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
The objective was to determine the effects of a single dose of migalastat hydrochloride (HCl) (migalastat) 150 and 450 milligrams (mg) on the safety and plasma pharmacokinetics (PK) of agalsidase and the effects of agalsidase on…
- Trial name
- NCT01196871
- Testing
- Migalastat HCl, Agalsidase Beta, Agalsidase Alfa
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 20 people
- Sponsor
- Amicus Therapeutics
Drug Interaction Potentiation
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects
- Trial name
- NCT03493698
- Testing
- Midazolam, Inarigivir
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- F-star Therapeutics, Inc.
Pharmacokinetics
Drug-Drug Interaction Study of Colchicine and Clarithromycin
Clarithromycin is a potent inhibitor of the activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp). CYP 3A4 plays a role in the metabolism of colchicine and P-gp is responsible for the efflux of colchicine across…
- Trial name
- NCT00984061
- Testing
- colchicine, clarithromycin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy
Drug-Drug Interaction Study Between Fenofibric Acid and Efavirenz
Efavirenz is predominantly metabolized by cytochrome P450 (CYP) 2B6. Fenofibric Acid is an inhibitor of CYP 2B6. This study will evaluate the effect of multiple doses of fenofibric acid at steady-state on the pharmacokinetics of…
- Trial name
- NCT00960570
- Testing
- Efavirenz 600 mg, Fenofibric Acid
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Brain and Central Nervous System Tumors
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients…
- Trial name
- NCT00068770
- Testing
- radiation therapy, Celecoxib
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Healthy
Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
This is a drug interaction study evaluating the pharmacokinetic profiles of Sulfamethoxazole administered alone \& in combination with Multi MatriX system (MMX®) formulation of mesalazine/mesalazine (Lialda®; Mesavancol®…
- Trial name
- NCT01469637
- Testing
- Sulfamethoxazole + MMX Mesalazine/mesalamine
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Participant
Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants
The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.
- Trial name
- NCT04962022
- Testing
- PF-07321332/ritonavir, Itraconazole
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Drug Interaction Study
Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117
This Study evaluates the Effect of St. John's Wort dry Extract Ze 117 on Several Cytochrome P450 Enzymes and on Transporter P-Glycoprotein in Healthy Volunteers.
- Trial name
- NCT03482817
- Testing
- Ze 117, Probe drug cocktail
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Max Zeller Soehne AG
Cannabidiol, Drug Induced Liver Injury
Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions
Cannabidiol (CBD) is available as a prescription drug product for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.
- Conditions
- Cannabidiol, Drug Induced Liver Injury, Drug Interaction
- Trial name
- NCT06192589
- Testing
- Cannabidiol, Citalopram, Morphine
- Where
- United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Migraine
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
- Trial name
- NCT04179474
- Testing
- Ubrogepant, Erenumab, Galcanezumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are…
- Trial name
- NCT05981365
- Testing
- Voxelotor, Bupropion, Repaglinide
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
The objective of the current study is to evaluate the effect of once daily itraconazole on the pharmacokinetics of BI 409306 in poor (PM) and extensive metabolisers (EM) of CYP2C19.
- Trial name
- NCT02248259
- Testing
- BI 409306, Itraconazole
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in…
- Trial name
- NCT04562116
- Testing
- Nemolizumab, CYP 450 Substrates
- Where
- 6 sites in United States, Bulgaria
- Volunteers
- 17 people
- Sponsor
- Galderma R&D
Drug-Drug Interaction, HIV Infection
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG)-based antiretroviral therapy (ART)…
- Trial name
- DPART (NCT04487145)
- Testing
- Dihydroartemisinin-piperaquine
- Where
- 2 sites in Uganda
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once…
- Trial name
- NCT04044001
- Testing
- BTZ-043, Rifafour e-275®, Probe Drug Cocktail
- Where
- 2 sites in South Africa
- Volunteers
- 78 people
- Sponsor
- Michael Hoelscher
Healthy
A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or…
- Trial name
- NCT05745701
- Testing
- PF-07081532, Cyclosporine, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer